Checkpoint inhibitors in ovarian cancer: A review of preclinical data
Ovarian cancer is the deadliest gynecologic malignancy, and relapse after initial treatment is frequently fatal. Although ovarian cancer typically has an immunosuppressive tumor microenvironment, a strong intratumoral T cell presence is associated with an improved response to chemotherapy and better...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2019-08-01
|
| Series: | Gynecologic Oncology Reports |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S235257891930058X |
| _version_ | 1818878283145543680 |
|---|---|
| author | David W. Doo Lyse A. Norian Rebecca C. Arend |
| author_facet | David W. Doo Lyse A. Norian Rebecca C. Arend |
| author_sort | David W. Doo |
| collection | DOAJ |
| description | Ovarian cancer is the deadliest gynecologic malignancy, and relapse after initial treatment is frequently fatal. Although ovarian cancer typically has an immunosuppressive tumor microenvironment, a strong intratumoral T cell presence is associated with an improved response to chemotherapy and better overall prognosis. Given the success of checkpoint inhibitors in the treatment of other malignancies, there has been an attempt to replicate these results in ovarian cancer clinical trials. Preclincal studies in ovarian cancer have also been conducted over the past decade, and most of the focus has been on the use of programmed cell death protein 1 (PD-1). Several other checkpoint inhibitors have also been investigated in various combinations with chemotherapy, oncolytic vaccines, co-stimulatory molecules, poly ADP ribose polymerase (PARP) inhibitors, and other checkpoint inhibitors. Unfortunately, these successes have yet to translate to the clinical realm. Whether this is because the drug class is truly ineffective in ovarian cancer, or simply because the research is lacking is unclear. Either way, it is evident that preclinical data on the use of checkpoint inhibitors is woefully deficient in ovarian cancer and more research is urgently needed to inform the translation of immune checkpoint blockade into successful clinical use. In this review, we discuss the results from preclinical studies using checkpoint inhibitors to treat ovarian cancer, with a focus on strategies that show potential for clinical use. Keywords: Ovarian cancer, Preclinical, Immune checkpoint inhibitors, Mouse model, Immunotherapy |
| first_indexed | 2024-12-19T14:11:43Z |
| format | Article |
| id | doaj.art-9add961f9fda44dfbce3d1fe75b05655 |
| institution | Directory Open Access Journal |
| issn | 2352-5789 |
| language | English |
| last_indexed | 2024-12-19T14:11:43Z |
| publishDate | 2019-08-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Gynecologic Oncology Reports |
| spelling | doaj.art-9add961f9fda44dfbce3d1fe75b056552022-12-21T20:18:07ZengElsevierGynecologic Oncology Reports2352-57892019-08-01294854Checkpoint inhibitors in ovarian cancer: A review of preclinical dataDavid W. Doo0Lyse A. Norian1Rebecca C. Arend2Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Alabama at Birmingham, Birmingham, AL, United States of AmericaDepartment of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL, United States of AmericaDepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Alabama at Birmingham, Birmingham, AL, United States of America; Corresponding author at: Division of Gynecologic Oncology, University of Alabama at Birmingham, 619 19th Street South, 176F Rm 10250, Birmingham, AL 35249, United States of America.Ovarian cancer is the deadliest gynecologic malignancy, and relapse after initial treatment is frequently fatal. Although ovarian cancer typically has an immunosuppressive tumor microenvironment, a strong intratumoral T cell presence is associated with an improved response to chemotherapy and better overall prognosis. Given the success of checkpoint inhibitors in the treatment of other malignancies, there has been an attempt to replicate these results in ovarian cancer clinical trials. Preclincal studies in ovarian cancer have also been conducted over the past decade, and most of the focus has been on the use of programmed cell death protein 1 (PD-1). Several other checkpoint inhibitors have also been investigated in various combinations with chemotherapy, oncolytic vaccines, co-stimulatory molecules, poly ADP ribose polymerase (PARP) inhibitors, and other checkpoint inhibitors. Unfortunately, these successes have yet to translate to the clinical realm. Whether this is because the drug class is truly ineffective in ovarian cancer, or simply because the research is lacking is unclear. Either way, it is evident that preclinical data on the use of checkpoint inhibitors is woefully deficient in ovarian cancer and more research is urgently needed to inform the translation of immune checkpoint blockade into successful clinical use. In this review, we discuss the results from preclinical studies using checkpoint inhibitors to treat ovarian cancer, with a focus on strategies that show potential for clinical use. Keywords: Ovarian cancer, Preclinical, Immune checkpoint inhibitors, Mouse model, Immunotherapyhttp://www.sciencedirect.com/science/article/pii/S235257891930058X |
| spellingShingle | David W. Doo Lyse A. Norian Rebecca C. Arend Checkpoint inhibitors in ovarian cancer: A review of preclinical data Gynecologic Oncology Reports |
| title | Checkpoint inhibitors in ovarian cancer: A review of preclinical data |
| title_full | Checkpoint inhibitors in ovarian cancer: A review of preclinical data |
| title_fullStr | Checkpoint inhibitors in ovarian cancer: A review of preclinical data |
| title_full_unstemmed | Checkpoint inhibitors in ovarian cancer: A review of preclinical data |
| title_short | Checkpoint inhibitors in ovarian cancer: A review of preclinical data |
| title_sort | checkpoint inhibitors in ovarian cancer a review of preclinical data |
| url | http://www.sciencedirect.com/science/article/pii/S235257891930058X |
| work_keys_str_mv | AT davidwdoo checkpointinhibitorsinovariancancerareviewofpreclinicaldata AT lyseanorian checkpointinhibitorsinovariancancerareviewofpreclinicaldata AT rebeccacarend checkpointinhibitorsinovariancancerareviewofpreclinicaldata |